Inositols: pharmacology and findings of clinical trials. Current evidence and prospects
DOI: 10.32364/2618-8430-2022-5-4-309-319
Yu.E. Dobrokhotova1, O.A. Gromova2, A.S. Dukhanin1, Z.Kh. Kumykova3, E.V. Sheremetyeva4, G.I. Tabeeva3
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2Federal Research Center "Informatics and Management" of the Russian Academy of Sciences, Moscow, Russian Federation
3V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russian Federation
4National Medical Research Center of Endocrinology, Moscow, Russian Federation
Alterations in reproductive functions are associated with metabolic disorders, eating habits and lifestyle. In this context, a growing body of research is currently focused on the use of various vitamins and vitamin-like substances, such as inositol, in female patients with alterations in reproductive functions and metabolic disorders. Co-administration of inositol with pathogenetic therapy can be recommended to women of reproductive age with metabolic syndrome, as an additional option for preserving fertility and activating ovarian functions in young female patients with diminished ovarian reserve. Myoinositol and D-chiroinositol are inositol stereoisomers demonstrating the highest metabolic activity. The beneficial ratio of Myoinositol (MI) to D-chiroinositol (DCI) ensures the healthy state of organs and tissues, while a misbalance or depletion of inositol levels can cause various diseases. Combination of MI and DCI in a 5:1 ratio with manganese and folic acid is an original non-hormonal formula designed to improve functional state of the female reproductive system as well as carbohydrate and lipid metabolism. In addition, this combination should be considered as a promising alternative for the management of metabolic disorders in perimenopausal women.
Keywords: reproductive function, metabolism, inositol, myoinositol, D-chiroinositol, polycystic ovary syndrome, ovarian reserve, menopause, metabolic syndrome, manganese, folic acid.
For citation: Dobrokhotova Yu.E., Gromova O.A., Dukhanin A.S. et al. Inositols: pharmacology and findings of clinical trials. Current evidence and prospects. Russian Journal of Woman and Child Health. 2022;5(4):309–319 (in Russ.). DOI: 10.32364/2618-8430-2022-5-4-309-319.
About the authors:
Yulia E. Dobrokhotova — Dr. Sc. (Med.), Head of the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0002-7830-2290.
Olga A. Gromova — Dr. Sc. (Med.), Professor, Research Director, Federal Research Center "Informatics and Management" of the Russian Academy of Sciences; 42, Vavilov str., Moscow, 119333, Russian Federation; ORCID iD 0000-0002-7663-710X.
Aleksandr S. Dukhanin — Dr. Sc. (Med.), Professor of the Department of Molecular Pharmacology and Radiobiology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0003-2433-7727.
Zaira Kh. Kumykova — C. Sc. (Med.), senior researcher of the Gynecological Department (Pediatric and Adolescent Gynecology), V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; 4, Academician Oparin str., Moscow, 117997, Russian Federation; ORCID iD 0000-0001-7511-1432.
Ekaterina V. Sheremetyeva — C. Sc. (Med.), leading researcher, National Medical Research Center of Endocrinology; 11, Dmitriy Ul’yanov str., Moscow, 117036, Russian Federation; ORCID iD 0000-0001-7177-0254.
Gyuzal I. Tabeeva — C. Sc. (Med.), senior researcher, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology; 4, Academician Oparin str., Moscow, 117997, Russian Federation; ORCID iD 0000-0003-1498-6520.
Contact information: Yulia E. Dobrokhotova, e-mail: pr.dobrohotova@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 07.10.2022.
Revised 01.11.2022.
Accepted 25.11.2022.
2. Majerus P.W., Wilson D.B., Zhang C. et al. Expression of inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) and its role in neural tube defects. Adv Enzyme Regul. 2010;50(1):365–372. DOI: 10.1016/j.advenzreg.2009.10.017.
3. Wilson M.P., Hugge C., Bielinska M. et al. Neural tube defects in mice with reduced levels of inositol 1,3,4-trisphosphate 5/6-kinase. Proc Natl Acad Sci U S A. 2009;106(24):9831–9835. DOI: 10.1073/pnas.0904172106.
4. Cogram P., Tesh S., Tesh J. et al. D-chiroinositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum Reprod. 2002;17(9):2451–2458. DOI: 10.1093/humrep/17.9.2451.
5. Gromova O.A., Torshin I.Yu., Tetruashvili N.K. Prospects of exogenous inositols in maintaining of skin, hair and nails condition: A review. Gynecology. 2022;24(4):261–270 (in Russ.). DOI: 10.26442/20795696.2022.4.201824.
6. Zhao M., Song B., Pu J. et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature. 2006;442(7101):457–460. DOI: 10.1038/nature04925.
7. Gromova O.A., Torshin I.Yu., Kalacheva A.G., Tetruashvili N.K. Roles of myo-inositol in maintaining women’s reproductive health. Increase effectiveness of in vitro fertilization techniques. Russian journal of Woman and Child Health. 2018;1(1):88–95 (in Russ.). DOI: 10.32364/2618-8430-2018-1-1-88-95.
8. Gromova O.A., Torshin I.Yu., Uvarova E.V. et al. Systematic analysis of the biological roles and pharmacological properties of D-chiroinositol. Gynecology. 2020;22(3):21–28 (in Russ.). DOI: 10.26442/20795696.2020.3.200210.
9. Fan C., Liang W., Wei M. et al. Effects of D-Chiroinositol on Glucose Metabolism in db/db Mice and the Associated Underlying Mechanisms. Front Pharmacol. 2020;11:354. DOI: 10.3389/fphar.2020.00354.
10. Ostlund R.E. Jr., McGill J.B., Herskowitz I. et al. D-chiroinositol metabolism in diabetes mellitus. Proc Natl Acad Sci U S A. 1993;90(21):9988–9992. DOI: 10.1073/pnas.90.21.9988.
11. La Marca A., Grisendi V., Dondi G. et al. The menstrual cycle regularization following D-chiroinositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol. 2015;31(1):52–56. DOI: 10.3109/09513590.2014.964201.
12. Iuorno M.J., Jakubowicz D.J., Baillargeon J.P. et al. Effects of d-chiroinositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8(6):417–423. DOI: 10.4158/EP.8.6.417.
13. Nestler J.E., Jakubowicz D.J., Reamer P. et al. Ovulatory and metabolic effects of D-chiroinositol in the polycystic ovary syndrome. N Engl J Med. 1999;340(17):1314–1320. DOI: 10.1056/NEJM199904293401703.
14. Maurizi A.R., Menduni M., Del Toro R. et al. A pilot study of D-chiroinositol plus folic acid in overweight patients with type 1 diabetes. Acta Diabetol. 2017;54(4):361–365. DOI: 10.1007/s00592-016-0954-x.
15. Malvasi A., Casciaro F., Minervini M.M. et al. Myo-inositol, D-chiroinositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2014;18(2):270–274. PMID: 24488919.
16. Cheng F., Han L., Xiao Y. et al. D-chiroinositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCe-PI3K/AKT Pathway. J Agric Food Chem. 2019;67(21):5957–5967. DOI: 10.1021/acs.jafc.9b01253.
17. Zhao S.S., Li N.R., Zhao W.L. et al. D-chiroinositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress. Acta Pharmacol Sin. 2018;39(2):213–221. DOI: 10.1038/aps.2017.98.
18. Torshin I.Yu., Gromova O.A., Tetruashvili N.K. Chemotranscriptome analysis of D-chiroinositol and myoinositol synergism in the context of postgenomic pharmacology. Obstetrics and gynecology. 2022;9:135–145 (in Russ.). DOI: 10.18565/aig.2022.9.135-145.
19. Inositol. (Electronic resource.) URL: https://go.drugbank.com/drugs/DB13178 (access date: 20.10.2022).
20. López-Gambero A.J., Sanjuan C., Serrano-Castro P.J. et al. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases. Biomedicines. 2020;8(9):295. DOI: 10.3390/biomedicines8090295.
21. Kiani A.K., Paolacci S., Calogero A.E. et al. From Myo-inositol to D-chiroinositol molecular pathways. Eur Rev Med Pharmacol Sci. 2021;25(5):2390–2402. DOI: 10.26355/eurrev_202103_25279.
22. Dinicola S., Unfer V., Facchinetti F. et al. Inositols: From Established Knowledge to Novel Approaches. Int J Mol Sci. 2021;22(19):10575. DOI: 10.3390/ijms221910575.
23. Lepore E., Lauretta R., Bianchini M. et al. Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies. Int J Mol Sci. 2021;22(13):6796. DOI: 10.3390/ijms22136796.
24. Garzon S., Laganà A.S., Monastra G. Risk of reduced intestinal absorption of myo-inositol caused by D-chiroinositol or by glucose transporter inhibitors. Expert Opin Drug Metab Toxicol. 2019;15:697–703. DOI: 10.1080/17425255.2019.1651839.
25. Thomas T.P., Feldman E.L., Nakamura J. et al. Ambient glucose and aldose reductase-induced myo-inositol depletion modulate basal and carbachol-stimulated inositol phospholipid metabolism and diacylglycerol accumulation in human retinal pigment epithelial cells in culture. Proc Natl Acad Sci U S A. 1993;90(20):9712–9716. DOI: 10.1073/pnas.90.20.9712.
26. Januszewski M., Issat T., Jakimiuk A.A. et al. Metabolic and hormonal effects of a combined Myo-inositol and d-chiroinositol therapy on patients with polycystic ovary syndrome (PCOS). Ginekol Pol. 2019;90(1):7–10. DOI: 10.5603/GP.2019.0002.
27. Mendoza N., Diaz-Ropero M.P., Aragon M. et al. Comparison of the effect of two combinations of myo-inositol and D-chiroinositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019;35(8):695–700. DOI: 10.1080/09513590.2019.1576620.
28. Facchinetti F., Dante G., Neri I. The Ratio of MI to DCI and Its Impact in the Treatment of Polycystic Ovary Syndrome: Experimental and Literature Evidences. In: Frontiers in Gynecological Endocrinology. Genazzani A., Tarlatzis B., eds. Springer; 2016:103–109. DOI: 10.1007/978-3-319-23865-4_13.
29. Carlomagno G., De Grazia S., Unfer V., Manna F. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv. 2012;9(3):267–271. DOI: 10.1517/17425247.2012.662953.
30. Nestler J.E., Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol. 2015;31(7):501–505. DOI: 10.3109/09513590.2015.1054802.
31. Bevilacqua A., Bizzarri M. Inositols in Insulin Signaling and Glucose Metabolism. Int J Endocrinol. 2018;2018:1968450. DOI: 10.1155/2018/1968450.
32. Ravanos K., Monastra G., Pavlidou T. et al. Can high levels of D-chiroinositol in follicular fluid exert detrimental effects on blastocyst quality? Eur Rev Med Pharmacol Sci. 2017;21(23):5491–5498. DOI: 10.26355/eurrev_201712_13940.
33. Thalamati S. A comparative study of combination of Myo-inositol and D-chiroinositol versus Metformin in the management of polycystic ovary syndrome in obese women with infertility. Int J Reprod Contracept Obstet Gynecol. 2019;8(3):825–829. DOI: 10.18203/2320-1770.ijrcog20190498.
34. Pkhaladze L., Russo M., Unfer V. et al. Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives. Eur Rev Med Pharmacol Sci. 2021;25(23):7476–7485. DOI: 10.26355/eurrev_202112_27447.
35. Owczarczyk-Saczonek A., Lahuta L.B., Ligor M. et al. The Healing-Promoting Properties of Selected Cyclitols-A Review. Nutrients. 2018;10(12):1891. DOI: 10.3390/nu10121891.
36. Kytikova O.Y., Antonyuk M.V., Kantur T.A. et al. Prevalence and biomarkers in metabolic syndrome. Obesity and metabolism. 2021;18(3):302–312 (in Russ.). DOI: 10.14341/omet12704.
37. Payette C., Blackburn P., Lamarche B. et al. Sex differences in postprandial plasma tumor necrosis factor-alpha, interleukin-6, and C-reactive protein concentrations. Metabolism. 2009;58(11):1593–1601. DOI: 10.1016/j.metabol.2009.05.011.
38. Metwally M., Li T.C., Ledger W.L. The impact of obesity on female reproductive function. Obes Rev. 2007;8(6):515–523. DOI: 10.1111/j.1467-789X.2007.00406.x.
39. Robker R.L., Akison L.K., Bennett B.D. et al. Obese women exhibit differences in ovarian metabolites, hormones, and gene expression compared with moderate-weight women. J Clin Endocrinol Metab. 2009;94(5):1533–1540. DOI: 10.1210/jc.2008-2648.
40. De Pergola G., Tartagni M., d’Angelo F. et al. Abdominal fat accumulation, and not insulin resistance, is associated to oligomenorrhea in non-hyperandrogenic overweight/obese women. J Endocrinol Invest. 2009;32(2):98–101. DOI: 10.1007/BF03345694.
41. Uchamprina V.A., Romantsova T.I., Kalashnikov M.F. Metabolic syndrome: аrguments pro’s and con’s. Obesity and metabolism. 2012;9(2):17–27 (in Russ.).
42. Iuorno M.J., Nestler J.E. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2001;28(1):153–164. DOI: 10.1016/s0889-8545(05)70191-1.
43. De Diego M.V., Gómez-Pardo O., Groar J.K. et al. Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study. Arch Gynecol Obstet. 2020;302(5):1169–1179. DOI: 10.1007/s00404-020-05696-y.
44. Agrawal A., Mahey R., Kachhawa G. et al. Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. Gynecol Endocrinol. 2019;35(6):511–514. DOI: 10.1080/09513590.2018.1549656.
45. Nordio M., Proietti E. The combined therapy with myo-inositol and D-chiroinositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012;16(5):575–581. PMID: 22774396.
46. Minozzi M., Nordio M., Pajalich R. The Combined therapy myo-inositol plus D-Chiroinositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013;17(4):537–540. PMID: 23467955.
47. Le Donne M., Metro D., Alibrandi A. et al. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiroinositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2019;23(5):2293–2301. DOI: 10.26355/eurrev_201903_17278.
48. Raffone E., Rizzo P., Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol. 2010;26(4):275–280. DOI: 10.3109/09513590903366996.
49. Roseff S., Montenegro M. Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary. Int J Endocrinol. 2020;2020:6461254. DOI: 10.1155/2020/6461254.
50. Gambioli R., Forte G., Aragona C. et al. The use of D-chiroinositol in clinical practice. Eur Rev Med Pharmacol Sci. 2021;25(1):438–446. DOI: 10.26355/eurrev_202101_24412.
51. Santamaria A., Di Benedetto A., Petrella E. et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. J Matern Fetal Neonatal Med. 2016;29(19):3234–3237. DOI: 10.3109/14767058.2015.1121478.
52. D’Anna R., Santamaria A., Alibrandi A. et al. Myo-Inositol for the Prevention of Gestational Diabetes Mellitus. A Brief Review. J Nutr Sci Vitaminol (Tokyo). 2019;65(Supplement):S59–S61. DOI: 10.3177/jnsv.65.S59.
53. Matarrelli B., Vitacolonna E., D’Angelo M. et al. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2013;26(10):967–972. DOI: 10.3109/14767058.2013.766691.
54. Kamenov Z., Gateva A. Inositols in PCOS. Molecules. 2020;25(23):5566. DOI: 10.3390/molecules25235566.
55. Oboskalova T.A., Vorontsova A.V., Zvychainyi M.A. et al. Results of treatment with myo-Inositol and D-chiro inositol combination in ratio 5:1 in women with. polycystic ovary syndrome. Gynecology. 2020;22(6):84–89 (in Russ.). DOI: 10.26442/20795696.2020.6.200548.
56. Dobrokhotova Yu.E., Lapina I.A., Chirvon T.G., Taranov V.V. New prospects of the integrative therapy for polycystic ovary syndrome in women with the disorders of carbohydrate and lipid metabolism: a comparative study. Russian Journal of Woman and Child Health. 2020;3(3):169–173 (in Russ.). DOI: 10.32364/2618-8430-2020-3-3-169-173.
57. Solov’yeva A.V., Fatkullin I.F., Akhmetgaliyev A.R. et al. Complex therapy of abnormal uterine bleeding in overweight and obese women using myoinositol and D-chiroinositol in a ratio of 5:1. Gynecology. 2021;23(5):402–406 (in Russ.). DOI: 10.26442/20795696.2021.5.201200.
58. Clinical guidelines. Menopause and menopause in women. ROAG. 2021 (in Russ.).
59. El Khoudary S.R., Greendale G., Crawford S.L. et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213–1227. DOI: 10.1097/GME.0000000000001424.
60. Zhang C., Zhao M., Li Z., Song Y. Follicle-Stimulating Hormone Positively Associates with Metabolic Factors in Perimenopausal Women. Int J Endocrinol. 2020;2020:7024321. DOI: 10.1155/2020/7024321.
61. Greendale G.A., Sternfeld B., Huang M. et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. DOI: 10.1172/jci.insight.124865.
62. AACE/ACE position statement on the prevention, diagnosis, and treatment of obesity (1998 revision). Endocr Pract 1998;4:297–350.
63. Fahed G., Aoun L., Bou Zerdan M. et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786. DOI: 10.3390/ijms23020786.
64. Giordano D., Corrado F., Santamaria A. et al. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause. 2011;18(1):102–104. DOI: 10.1097/gme.0b013e3181e8e1b1.
65. Santamaria A., Giordano D., Corrado F. et al. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric. 2012;15(5):490–495. DOI: 10.3109/13697137.2011.631063.
66. D’Anna R., Santamaria A., Cannata M.L. et al. Effects of a new flavonoid and Myo-inositol supplement on some biomarkers of cardiovascular risk in postmenopausal women: a randomized trial. Int J Endocrinol. 2014;2014:653561. DOI: 10.1155/2014/653561.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
